CONDENSED CONSOLIDATED STATEMENTS OF INCOME (OPERATIONS) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue
Total operating revenue	$ 55,161	$ 48,580
Operating expenses
Selling, general and administrative expense	29,806	11,178
Depreciation and amortization	987	777
Total operating expenses	73,632	50,333
Loss from operations	(18,471)	(1,753)
Other non-operating expense (income)
Interest expense	74	101
Change in fair value of derivative warrant liabilities	1,461	0
Change in fair value of earnout liabilities	(39,440)	0
Gain on debt extinguishment	(183)	0
Other, net	151	(1,076)
Total other non-operating income	(37,937)	(975)
Income before provision for income (loss) taxes	19,466	(778)
Income tax expense	(180)	(218)
Net income (loss)	$ 19,286	$ (996)
Net income (loss) per share attributable to common stockholders:
Basic (in usd per share)	$ 0.22	$ (0.02)
Diluted (in usd per share)	$ 0.21	$ (0.02)
Weighted-average number of shares outstanding:
Basic (in shares)	73,252,365	62,853,419
Diluted (in shares)	76,247,966	62,853,419
Patient services
Revenue
Total operating revenue	$ 35,057	$ 29,622
Operating expenses
Direct costs	27,378	23,086
Dispensary
Revenue
Total operating revenue	18,679	17,618
Operating expenses
Direct costs	15,324	15,123
Clinical trials & other
Revenue
Total operating revenue	1,425	1,340
Operating expenses
Direct costs	$ 137	$ 169